carbostyril has been researched along with Koch's Disease in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.94) | 18.7374 |
| 1990's | 10 (29.41) | 18.2507 |
| 2000's | 7 (20.59) | 29.6817 |
| 2010's | 13 (38.24) | 24.3611 |
| 2020's | 3 (8.82) | 2.80 |
| Authors | Studies |
|---|---|
| Beteck, RM; Dube, PS; Legoabe, LJ | 1 |
| Bulychev, VV; Bulycheva, EV; Pashkova, NA | 1 |
| Kantevari, S; Krishna, VS; Marvadi, SK; Sridhar, B; Srilakshmi Reshma, R; Sriram, D; Surineni, G | 1 |
| Llerena, C; Murcia, M; Valbuena, A; Zabaleta, A | 1 |
| Ahmed, S; Nandi, S; Saxena, AK | 1 |
| Bishai, WR; Gupta, S; Isaacs, JT; Krug, S; Leanderson, T; Pokkali, S; Srikrishna, G | 1 |
| Beteck, RM; Hoppe, HC; Jordaan, A; Khanye, SD; Laming, D; Seldon, R; Warner, DF | 1 |
| Keynan, Y; Rubinstein, E | 1 |
| Jardosh, HH; Patel, MP | 1 |
| Monneret, C | 1 |
| Chuah, SK; Hu, TH; Lee, CH; Liang, CM; Tai, WC | 1 |
| Bhakta, S; Bucar, F; Evangelopoulos, D; Guzman, JD; Hochfellner, C; Kunert, O; McHugh, TD; Wube, A; Zloh, M | 1 |
| Kim, H; Nakajima, C; Suzuki, Y; Yamaguchi, T; Yokoyama, K | 1 |
| Keum, YS; Park, SW; Patel, RV | 1 |
| Bellamy, R; Payne, B | 1 |
| Chou, CH; Hsu, HL; Hsueh, PR; Huang, YT; Lai, CC; Liao, CH; Tan, CK | 1 |
| Ekambaram, R; Raghunathan, M; Raghunathan, R; Rao, SS | 1 |
| Ackerman, M; Cynamon, MH; Pucci, MJ; Shoen, CM; Thanassi, JA | 1 |
| Chang, YK; Choi, BS; Chung, HW; Hwang, HS; Jeon, YJ; Kim, SY; Kim, YS; Lee, SJ; Park, CW; Shin, SJ; Yang, CW; Yoon, HE | 1 |
| Böhle, A; Fornara, P; Jocham, D; Jurczok, A; Zacharias, M | 1 |
| Barry, CE; Duncan, K | 1 |
| Yeager, H | 1 |
| Singh, A | 1 |
| Grosset, J; JI, B; Lounis, N; Truffot-Pernot, C | 1 |
| Davies, PD; Grange, JM; Winstanley, PA | 1 |
| Gillespie, SH; Kennedy, N | 1 |
| Makarova, OV; Mikhaĭlova, LP; Mozhokina, GN; Sokolova, GB | 1 |
| Bonnafous, P; Grosset, J; Ji, B; Lounis, N; Maslo, C; Truffot-Pernot, C | 1 |
| Cohen, Y; Grosset, J; Perronne, C; Pocidalo, JJ; Truffot-Pernot, C; Vildé, JL | 1 |
| Cynamon, MH; DeStefano, MS; Klemens, SP | 1 |
| Grosset, JH | 1 |
| Saito, H; Sato, K; Tomioka, H | 1 |
| Grosset, J; Ji, B; Truffot-Pernot, C | 1 |
| Haemers, A; Leysen, DC; Pattyn, SR | 1 |
12 review(s) available for carbostyril and Koch's Disease
| Article | Year |
|---|---|
Quinolone: a versatile therapeutic compound class.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Fluoroquinolones; Humans; Quinolones; Tuberculosis | 2023 |
Quinolones for mycobacterial infections.
Topics: Anti-Bacterial Agents; Humans; Leprosy; Quinolones; Treatment Outcome; Tuberculosis | 2013 |
[Two news drugs (ivacaftor & bedaquiline), one biomarker (florbetapir) and a re-positioned drug (propranolol) on the market].
Topics: Adrenergic beta-Antagonists; Adult; Alzheimer Disease; Aminophenols; Aniline Compounds; Antitubercular Agents; Cystic Fibrosis; Diarylquinolines; Drug Resistance, Bacterial; Ethylene Glycols; Hemangioma; Humans; Infant; Propranolol; Quinolones; Radionuclide Imaging; Radiopharmaceuticals; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2014 |
Quinolone-containing therapies in the eradication of Helicobacter pylori.
Topics: Disease Eradication; Helicobacter Infections; Helicobacter pylori; Humans; Quinolones; Tuberculosis | 2014 |
[What Hansen's disease research learned from tuberculosis research: from molecular biological aspect].
Topics: Antibiotics, Antitubercular; DNA Gyrase; Drug Resistance, Microbial; Humans; Leprosy; Molecular Biology; Mutation; Mycobacterium leprae; Mycobacterium tuberculosis; Quinolones; Research; Rifampin; Tuberculosis | 2014 |
Nitroimidazoles, Quinolones and Oxazolidinones as Fluorine Bearing Antitubercular Clinical Candidates.
Topics: Animals; Antitubercular Agents; Drug Discovery; Fluorine; Humans; Nitroimidazoles; Oxazolidinones; Quinolones; Tuberculosis | 2015 |
Tuberculosis in people with HIV.
Topics: Disease Progression; HIV Infections; Humans; Meta-Analysis as Topic; Quinolones; Survival Analysis; Time Factors; Tuberculosis; United States Food and Drug Administration | 2007 |
Prospects for new antitubercular drugs.
Topics: Animals; Antitubercular Agents; Drug Evaluation, Preclinical; Humans; Mycobacterium tuberculosis; Quinolones; Rifamycins; Tuberculosis | 2004 |
New drugs and vaccines.
Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Fluoroquinolones; Humans; Mycobacterium bovis; Mycobacterium tuberculosis; Nitroimidazoles; Quinolones; Rifamycins; Tuberculosis; Tuberculosis Vaccines; World Health Organization | 2007 |
Clinically significant drug interactions with antituberculosis agents.
Topics: Absorption; Antitubercular Agents; Biotransformation; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Enzyme Induction; Humans; Isoenzymes; Isoniazid; Quinolones; Rifabutin; Rifampin; Tissue Distribution; Tuberculosis | 1994 |
Treatment of tuberculosis in HIV infection.
Topics: AIDS-Related Opportunistic Infections; Animals; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Fluoroquinolones; Humans; Mice; Quinolones; Tuberculosis | 1992 |
Mycobacteria and the new quinolones.
Topics: Animals; Humans; Leprosy; Mice; Microbial Sensitivity Tests; Mycobacterium; Mycobacterium Infections; Mycobacterium leprae; Mycobacterium tuberculosis; Quinolones; Tuberculosis | 1989 |
2 trial(s) available for carbostyril and Koch's Disease
| Article | Year |
|---|---|
Safety and efficacy of a quinolone-based regimen for treatment of tuberculosis in renal transplant recipients.
Topics: Adult; Antitubercular Agents; Female; Humans; Kidney Transplantation; Male; Middle Aged; Quinolones; Tuberculosis | 2012 |
Clinically significant drug interactions with antituberculosis agents.
Topics: Absorption; Antitubercular Agents; Biotransformation; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Enzyme Induction; Humans; Isoenzymes; Isoniazid; Quinolones; Rifabutin; Rifampin; Tissue Distribution; Tuberculosis | 1994 |
21 other study(ies) available for carbostyril and Koch's Disease
| Article | Year |
|---|---|
[The problem of formation of new risks of medicinal resistance of patients with tuberculosis in condition of active use of antibiotics by population under COVID-19].
Topics: Anti-Infective Agents; Antitubercular Agents; Azithromycin; COVID-19; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Mycobacterium tuberculosis; Pandemics; Quinolones; Tuberculosis | 2023 |
Synthesis, in vitro, and in vivo (Zebra fish) antitubercular activity of 7,8-dihydroquinolin-5(6H)-ylidenehydrazinecarbothioamides.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Design; Humans; Hydrazines; Microbial Sensitivity Tests; Molecular Docking Simulation; Mycobacterium tuberculosis; Quinolones; Structure-Activity Relationship; Thioamides; Tuberculosis; Zebrafish | 2020 |
[Prevalence of Mycobacterium tuberculosis resistance to quinolones and injectables in Colombia, 2012-2013].
Topics: Antitubercular Agents; Colombia; Cross-Sectional Studies; Humans; Isoniazid; Mycobacterium tuberculosis; Prevalence; Quinolones; Rifampin; Tuberculosis | 2017 |
Combinatorial design and virtual screening of potent anti-tubercular fluoroquinolone and isothiazoloquinolone compounds utilizing QSAR and pharmacophore modelling.
Topics: Antitubercular Agents; Drug Design; Fluoroquinolones; Models, Molecular; Mycobacterium fortuitum; Mycobacterium smegmatis; Quantitative Structure-Activity Relationship; Quinolones; Thiazoles; Tuberculosis | 2018 |
Pharmacologic Exhaustion of Suppressor Cells with Tasquinimod Enhances Bacterial Clearance during Tuberculosis.
Topics: Animals; Disease Models, Animal; Mice; Myeloid-Derived Suppressor Cells; Quinolones; T-Lymphocytes, Regulatory; Tuberculosis | 2019 |
New Quinolone-Based Thiosemicarbazones Showing Activity Against
Topics: Animals; Anti-Infective Agents; Candy; Drug Interactions; HeLa Cells; Humans; Inhibitory Concentration 50; Malaria, Falciparum; Molecular Structure; Mycobacterium tuberculosis; Plasmodium falciparum; Quinolones; Small Molecule Libraries; Thiosemicarbazones; Tuberculosis | 2019 |
Design and synthesis of biquinolone-isoniazid hybrids as a new class of antitubercular and antimicrobial agents.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Antitubercular Agents; Artemia; Bacteria; Dose-Response Relationship, Drug; Drug Design; Fungi; Isoniazid; Microbial Sensitivity Tests; Molecular Structure; Motor Activity; Quinolones; Structure-Activity Relationship; Tuberculosis | 2013 |
Antagonistic effects of indoloquinazoline alkaloids on antimycobacterial activity of evocarpine.
Topics: Alkaloids; Anti-Bacterial Agents; Drug Antagonism; Humans; Mycobacterium tuberculosis; Plant Extracts; Quinazolines; Quinolones; Tuberculosis | 2015 |
Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Fluoroquinolones; Gemifloxacin; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Naphthyridines; Quinolones; Tuberculosis | 2009 |
In vitro activities of the newly synthesised ER-2 against clinical isolates of Mycobacterium tuberculosis susceptible or resistant to antituberculosis drugs.
Topics: Animals; Antitubercular Agents; Colony Count, Microbial; Female; Humans; Lung; Mice; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Quinolones; Spleen; Treatment Outcome; Tuberculosis | 2009 |
In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
Topics: Antitubercular Agents; DNA Gyrase; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Quinolones; Thiazoles; Topoisomerase II Inhibitors; Tuberculosis | 2010 |
[Experimental investigations of the optimal therapy of systemic BCG infection in vivo].
Topics: Adrenal Cortex Hormones; Aged; Animals; Anti-Bacterial Agents; Antitubercular Agents; BCG Vaccine; Data Interpretation, Statistical; Disease Models, Animal; Female; Humans; Hypersensitivity; Immunotherapy; Male; Mice; Mice, Inbred C57BL; Mycobacterium bovis; Quinolones; Time Factors; Tuberculosis; Tumor Cells, Cultured; Urinary Bladder; Urinary Bladder Neoplasms | 2004 |
Quinolones to treat acute bacterial exacerbation of chronic bronchitis in TB endemic areas: a word of caution.
Topics: Bronchitis, Chronic; Endemic Diseases; Humans; Mycobacterium tuberculosis; Quinolones; Randomized Controlled Trials as Topic; Tuberculosis | 2007 |
In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis.
Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Isomerism; Isoniazid; Levofloxacin; Lung; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ofloxacin; Quinolones; Spleen; Splenomegaly; Survival Rate; Tuberculosis | 1995 |
Treatment of tuberculosis in HIV infection.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antitubercular Agents; Fluoroquinolones; Humans; Quinolones; Tuberculosis | 1993 |
[Antitubercular activity of lomefloxacin in an experiment].
Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fluoroquinolones; Isoniazid; Lung; Mice; Mycobacterium tuberculosis; Quinolones; Reference Values; Spleen; Survival Rate; Tuberculosis | 1996 |
In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Female; Fluoroquinolones; Lung; Mice; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Organ Size; Quinolines; Quinolones; Spleen; Tuberculosis | 1998 |
Sparfloxacin, ethambutol, and cortisol receptor inhibitor RU-40 555 treatment for disseminated Mycobacterium avium complex infection of normal C57BL/6 mice.
Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Drug Therapy, Combination; Ethambutol; Feasibility Studies; Female; Fluoroquinolones; Glucocorticoids; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mifepristone; Mycobacterium avium; Quinolones; Receptors, Glucocorticoid; Spleen; Time Factors; Tuberculosis | 1992 |
Activity of clarithromycin against Mycobacterium avium complex infection in beige mice.
Topics: Amikacin; Animals; Anti-Infective Agents; Antitubercular Agents; Clarithromycin; Clofazimine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Humans; Mice; Mice, Inbred C57BL; Mycobacterium avium; Mycobacterium avium Complex; Quinolones; Rifabutin; Rifampin; Rifamycins; Time Factors; Tuberculosis | 1992 |
[Antimycobacterial activities of a new quinolone, sparfloxacin].
Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Drug Resistance, Microbial; Fluoroquinolones; Mice; Mycobacterium; Mycobacterium avium; Mycobacterium tuberculosis; Quinolones; Tuberculosis | 1991 |
In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis.
Topics: Animals; Anti-Infective Agents; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ofloxacin; Quinolones; Tuberculosis | 1991 |